Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
74 studies found for:    vaccine adverse reactions | Open Studies
Show Display Options
Rank Status Study
21 Not yet recruiting Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol
Condition: Tuberculosis
Intervention: Biological: Ad5Ag85A
22 Recruiting Polysaccharide Antibody Response Study
Condition: Specific Polysaccharide Antibody Deficiency
Interventions: Biological: Pneumovax 23 (Sanofi Pasteur MSD);   Biological: Typhim Vi (Sanofi Pasteur MSD)
23 Recruiting Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector
Condition: Severe Combined Immunodeficiency
Intervention: Biological: Gene transfer
24 Recruiting The PertADO Geneva Trial
Condition: Pertussis
Interventions: Biological: Pertagen® aP + Td-pur®;   Biological: Boostrix® dTpa
25 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
26 Recruiting Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam
Conditions: Meningitis;   Meningococcal Meningitis;   Meningococcal Infections
Intervention: Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
27 Recruiting Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years
Condition: Chlamydia Trachomatis
Interventions: Biological: CTH522-CAF01;   Biological: CTH522-Al(OH)3;   Biological: Placebo
28 Recruiting Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults
Condition: Malaria
Interventions: Biological: PRIMVAC;   Biological: GLA-SE;   Biological: Alhydrogel;   Biological: Placebo
29 Recruiting Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
Condition: Japanese Encephalitis
Intervention: Biological: IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
30 Recruiting Phase 1 Trial of PAN-301-1 in Cancer Patients
Condition: Prostate Cancer
Intervention: Biological: PAN-301-1
31 Recruiting Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Conditions: HER2/Neu Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu Intracellular Domain Protein;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Placebo;   Biological: Polysaccharide-K;   Biological: Trastuzumab
32 Not yet recruiting Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Conditions: Pancreatic Cancer;   Pancreas Cancer;   Cancer of the Pancreas
Interventions: Biological: Personalized neoantigen DNA vaccine;   Device: TDS-IM Electrode Array System;   Procedure: Peripheral blood draws
33 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Hemorrhagic Fever, Ebola
Intervention: Procedure: blood sampling collection
34 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
35 Recruiting DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Polio;   Human Immunodeficiency Virus Infection
Intervention: Biological: Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
36 Recruiting Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
Condition: Malaria
Interventions: Biological: Pfs25M-EPA/AS01;   Biological: Pfs230D1M-EPA/AS01;   Other: AS01;   Biological: Bexsero (Comparator Vaccine);   Biological: Fluarix;   Other: Normal Saline;   Drug: Coartem
37 Recruiting A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
Condition: Pneumococcal Infections
Intervention: Biological: Pneumococcal conjugate vaccine
38 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Colon Carcinoma;   Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   Hepatocellular Carcinoma;   HER2/Neu Negative;   Melanoma;   Non-Small Cell Lung Carcinoma;   Pancreatic Carcinoma;   Progesterone Receptor Negative;   Rectal Carcinoma;   Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Triple-Negative Breast Carcinoma;   TP53 Gene Mutation;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53;   Biological: Pembrolizumab
39 Recruiting Protecting From Pneumococcus in Early Life (The PROPEL Trial)
Condition: Pneumonia
Interventions: Biological: 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid;   Biological: placebo 0.9% sodium chloride plus tetanus toxoid;   Other: tetanus toxoid
40 Recruiting Introducing PrEP Into HIV Combination Prevention - Kenya
Condition: HIV
Intervention: Drug: Truvada

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.